gsk201303046k3.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending March 2013
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
Vesting of conditional share awards under the
GlaxoSmithKline Share Value Plan
This notification sets out the vesting of awards over Ordinary Shares and American Depositary Shares (ADS) in GlaxoSmithKline plc, made in 2010 under the GlaxoSmithKline Share Value Plan (SVP), which were conditional on continued employment with the GlaxoSmithKline group.
The three-year vesting period for the 2010 SVP awards, which commenced on 23 February 2010, has now ended. The awards made to the connected persons of a Director and of a Person Discharging Managerial Responsibility (PDMR) vested on 1 March 2013 and details are given in the table below.
|
Name of
Director / PDMR
|
Name of Connected person
|
Number of ADS
vested
|
Number of Ordinary Shares vested
|
|
Mr P Thomson
|
Mrs K Thomson
|
|
837
|
|
Dr M Slaoui*
|
Mrs K Slaoui
|
640
|
|
* Denotes an Executive Director
The Company and the above individuals were advised of these transactions on 1 March 2013.
The fair market values of an Ordinary Share and of an ADS of GlaxoSmithKline plc at the point of vesting on 1 March 2013 were £14.55 and US$44.03 respectively.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
V A Whyte
Company Secretary
4 March 2013
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: March 04, 2013
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc